![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Comparative and Molecular Pharmacogenetics Laboratory (M.H.C., S.K., Q.H., S.X.D.) and Clinical Pharmacology Laboratory (L.L.v.M., D.J.G.), Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts; and BD Gentest (C.J.P.), Woburn, Massachusetts
UDP-glucuronosyltransferase 2B7 (UGT2B7) is involved in the glucuronidation of a wide array of clinically important drugs and endogenous compounds in humans. The aim of this study was to identify an isoform-selective probe substrate that could be used to investigate genetic and environmental influences on glucuronidation mediated by UGT2B7. Three potential probe substrates [3'-azido-3'-deoxythymidine (AZT), morphine, and codeine], were evaluated using recombinant UGTs and human liver microsomes (HLMs; n = 54). Of 11 different UGTs screened, UGT2B7 was the principal isoform mediating AZT glucuronidation, morphine-3-glucuronidation, and morphine-6-glucuronidation. Codeine was glucuronidated equally well by UGT2B4 and UGT2B7. Enzyme kinetic analysis of these activities typically showed higher apparent Km values for HLMs (pooled and individual) compared with UGT2B7. This difference was least (less than 2-fold higher Km) for AZT glucuronidation and greatest (3- to 6-fold higher Km) for codeine glucuronidation. Microsomal UGT2B7 protein content correlated well with AZT glucuronidation (rs = 0.77), to a lesser extent with morphine-3-glucuronidation (rs = 0.50) and morphine-6-glucuronidation (rs = 0.51), but very weakly with codeine glucuronidation (rs = 0.33). Livers were also genotyped for the UGT2B7*2 (H268Y) polymorphism. No effect of genotype on microsomal glucuronidation or UGT2B7 protein content was observed. In conclusion, although both AZT and morphine can serve as in vitro probe substrates for UGT2B7, AZT appears to be more selective than morphine. Codeine is not a useful UGT2B7 probe substrate because of significant glucuronidation by UGT2B4. The UGT2B7*2 polymorphism is not a determinant of glucuronidation of AZT, morphine, or codeine in HLMs.
This article has been cited by other articles:
|
|
 |
|
  J. Tojcic, M.-O. Benoit-Biancamano, M. H. Court, R. J. Straka, P. Caron, and C. Guillemette In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes Drug Metab. Dispos., November 1, 2009; 37(11): 2236 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kwara, M. Lartey, I. Boamah, N. L. Rezk, J. Oliver-Commey, E. Kenu, A. D. M. Kashuba, and M. H. Court Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation J. Clin. Pharmacol., September 1, 2009; 49(9): 1079 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Balliet, G. Chen, C. J. Gallagher, R. W. Dellinger, D. Sun, and P. Lazarus Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype Cancer Res., April 1, 2009; 69(7): 2981 - 2989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Uchaipichat, A. Galetin, J. B. Houston, P. I. Mackenzie, J. A. Williams, and J. O. Miners Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites Mol. Pharmacol., October 1, 2008; 74(4): 1152 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-X. Liu, Y. Liu, J.-W. Zhang, W. Li, H.-T. Liu, and L. Yang UDP-Glucuronosyltransferase 1A6 Is the Major Isozyme Responsible for Protocatechuic Aldehyde Glucuronidation in Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities Drug Metab. Dispos., June 1, 2008; 36(6): 1056 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohno, K. Kawana, and S. Nakajin Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties Drug Metab. Dispos., April 1, 2008; 36(4): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, D. Zhang, D. Cui, J. Gambardella, L. Ma, A. Barros, L. Wang, Y. Fu, S. Rahematpura, J. Nielsen, et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism Drug Metab. Dispos., December 1, 2007; 35(12): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Racemic Flurbiprofen in the Human Liver Drug Metab. Dispos., July 1, 2007; 35(7): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura Comparison of Inhibition Potentials of Drugs against Zidovudine Glucuronidation in Rat Hepatocytes and Liver Microsomes Drug Metab. Dispos., April 1, 2007; 35(4): 602 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rowland, P. Gaganis, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wen, D. E. Martin, P. Bullock, K.-H. Lee, and P. C. Smith Glucuronidation of Anti-HIV Drug Candidate Bevirimat: Identification of Human UDP-glucuronosyltransferases and Species Differences Drug Metab. Dispos., March 1, 2007; 35(3): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bowalgaha, D. J. Elliot, P. I. Mackenzie, K. M. Knights, and J. O. Miners The Glucuronidation of {Delta}4-3-Keto C19- and C21-Hydroxysteroids by Human Liver Microsomal and Recombinant UDP-glucuronosyltransferases (UGTs): 6{alpha}- and 21-Hydroxyprogesterone Are Selective Substrates for UGT2B7 Drug Metab. Dispos., March 1, 2007; 35(3): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeda, Y. Kitajima, Y. Ishii, Y. Nishimura, P. I. Mackenzie, K. Oguri, and H. Yamada INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE Drug Metab. Dispos., August 1, 2006; 34(8): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) "PROBES" FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., March 1, 2006; 34(3): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, K. Johnson, J. Paulauskis, and J. Cook So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol., March 1, 2006; 46(3): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Engtrakul, R. S. Foti, T. J. Strelevitz, and M. B. Fisher ALTERED AZT (3'-AZIDO-3'-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT Drug Metab. Dispos., November 1, 2005; 33(11): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnaswamy, Q. Hao, A. Al-Rohaimi, L. M. Hesse, L. L. von Moltke, D. J. Greenblatt, and M. H. Court UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5'-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1331 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-f. Lin, W.-c. Guo, J.-g. Chen, Y.-q. Qin, K. Golka, C.-q. Xiang, Q.-w. Ma, D.-r. Lu, and J.-h. Shen An Association of UDP-Glucuronosyltransferase 2B7 C802T (His268Tyr) Polymorphism with Bladder Cancer in Benzidine-Exposed Workers in China Toxicol. Sci., May 1, 2005; 85(1): 502 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kaji and T. Kume REGIOSELECTIVE GLUCURONIDATION OF DENOPAMINE: MARKED SPECIES DIFFERENCES AND IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ISOFORM Drug Metab. Dispos., March 1, 2005; 33(3): 403 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeda, Y. Ishii, M. Iwanaga, P. I. Mackenzie, K. Nagata, Y. Yamazoe, K. Oguri, and H. Yamada Modulation of UDP-Glucuronosyltransferase Function by Cytochrome P450: Evidence for the Alteration of UGT2B7-Catalyzed Glucuronidation of Morphine by CYP3A4 Mol. Pharmacol., March 1, 2005; 67(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garland, K. M. Abildskov, T.-w. Kiu, S. S. Daniel, and R. I. Stark THE CONTRIBUTION OF FETAL METABOLISM TO THE DISPOSITION OF MORPHINE Drug Metab. Dispos., January 1, 2005; 33(1): 68 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Picard, D. Ratanasavanh, A. Premaud, Y. Le Meur, and P. Marquet IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM Drug Metab. Dispos., January 1, 2005; 33(1): 139 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Caraco Genes and the Response to Drugs N. Engl. J. Med., December 30, 2004; 351(27): 2867 - 2869. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zapor, K. L. Cozza, G. H. Wynn, G. W. Wortmann, and S. C. Armstrong Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors) Psychosomatics, December 1, 2004; 45(6): 524 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saeki, Y. Saito, H. Jinno, T. Tanaka-Kagawa, A. Ohno, S. Ozawa, K. Ueno, S. Kamakura, N. Kamatani, K. Komamura, et al. SINGLE NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPE FREQUENCIES OF UGT2B4 AND UGT2B7 IN A JAPANESE POPULATION Drug Metab. Dispos., September 1, 2004; 32(9): 1048 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnaswamy, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and M. H. Court EVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 1A6 Drug Metab. Dispos., August 1, 2004; 32(8): 862 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Al-Rohaimi, L. L. von Moltke, and D. J. Greenblatt UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 656 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Uchaipichat, P. I. Mackenzie, X.-H. Guo, D. Gardner-Stephen, A. Galetin, J. B. Houston, and J. O. Miners HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID Drug Metab. Dispos., April 1, 2004; 32(4): 413 - 423. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
